Jean-François Rivassou (Kurma Partners (Kurma Life Sciences Partners))

Rivassou, Jean-François (Kurma Partners 202104– Partner before ISAI Gestion + Adenclassifieds + Banexi Ventures)

	Organisation	Kurma Partners (Kurma Life Sciences Partners)
	Group	Eurazeo (Group)
	Former/major organisation	ISAI Gestion
	Group	ISAI (Group)
	Product	venture capital
	Product 2	LIFE SCIENCES

Kurma Partners. (4/13/21). "Press Release: Jean-François Rivassou Joins Kurma Partners as Partner". Paris.

Kurma Partners, a leading European venture capital company in the field of Life Sciences based in Paris and Munich with nearly 500 million euros under management, today announced the appointment of Jean-François Rivassou as Partner.

Jean-François Rivassou, 45, has been appointed as Partner to further support Kurma Partners life sciences portfolio companies in their late-stage development.

Jean-François was previously in charge of growth and private equity investments at ISAI Gestion, a Paris based tech fund. From 2006 to 2012, he was Head of M&A and Business Development, and a member of Adenclassifieds’ management committee, a digital company listed on Euronext Paris. Prior Adenclassifieds, he worked as an investment manager at Banexi Ventures Partners, a BNP Paribas backed VC fund, where he was responsible for biotech and medtech investments. Jean-François started his career at Genset, a Euronext and Nasdaq listed genomics company, in the group’s Singaporean subsidiary. Jean-François graduated from the Ecole Nationale Supérieure des Mines de Paris, a leading generalist engineering school, where he specialized in Biotechnology.

In a context of increasing maturity of the European Life Sciences ecosystem, the appointment of Jean-François illustrates Kurma Partners’ ambition to strengthen, in an integrated manner, its expertise in the more advanced phases of development of its portfolio companies.

About Kurma Partners : www.kurmapartners.com

Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).

NewCap

Nicolas Merigeau
Medias Relations
Phone nb.: +33 (0)1 44 71 94 98
Email: nmerigeau@newcap.fr